காடிலா சுகாதாரம் லிமிடெட் ஜய்துச் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from காடிலா சுகாதாரம் லிமிடெட் ஜய்துச். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In காடிலா சுகாதாரம் லிமிடெட் ஜய்துச் Today - Breaking & Trending Today

Multiples Alternate Asset Mgt-led group to buy Cadila's animal health biz


Cadila Healthcare Ltd (Zydus Cadila) s wholly-owned material subsidiary Zydus Animal Health and Investments Limited (ZAHL) is set to sell its animal healthcare business to a consortium led by Multiples Alternate Asset Management for nearly Rs 3,000 crore.
Zydus Cadila on Wednesday announced that ZAHL has entered into a business transfer agreement (BTA) and other ancillary agreements to sell and transfer Zydus AH, its animal healthcare established markets undertaking to the Multiples-led consortium.
The deal is to sell one of the two business undertakings of ZAHL on a slump sale basis as a going concern, for a lump sum consideration of Rs 2,921 crore on a cash-free and debt-free basis, subject to certain closing date adjustments and other conditions. The transaction involves transfer of immovable assets, movable assets, inventory, brands and intangible assets, contracts, licenses and permissions, business records, employees along with employee benefit funds, insurance pol ....

Pankaj Patel , Renuka Ramnath , Arun Atrey , Zenex Animal Health India Private , Moelis Co , Cadila Healthcare Ltd Zydus , Cyril Amarchand Mangaldas Co , Investments Limited , Enterprises Partner Rakesh Jhunjhunwala , Zydus Animal Health , Cadila Healthcare Ltd , Zydus Cadila , Multiples Alternate Asset Management , Canada Pension Plan Investment Board , Cadila Healthcare , Managing Director , Partner Rakesh Jhunjhunwala , Cyril Amarchand Mangaldas , Health Care , Healthcare Sector , Healthcare Firms , Healthcare Companies , Healthcare Stocks , Healthcare Startups , பங்கஜ் படேல் , ரேணுகா ராம்நாத் ,

Zydus seeks DCGI nod for add'l indication of Hep C drug in Covid-19 therapy


With the phase-3 clinical trials of its Pegylated Interferon Alpha 2b therapy, PegiHep, showing promising results, Cadila Healthcare Ltd (Zydus Cadila) has applied for an approval for additional indication with the Drugs Controller General of India (DCGI) for the use of PegIFN in the treatment of Covid-19.
In what could be a breakthrough in the disease management of Covid-19, the interim results indicate that PegIFN when administered early on, could help patients recover faster and avoid much of the complications seen in the advanced stages of the disease.
According to Zydus Cadila, PegIFN in Covid-19 has several add-on advantages compared to other anti-viral agents with the treatment regimen being less cumbersome and more affordable for patients as Pegylated Interferon Alpha 2b, is a single dose regimen. ....

Zydus Cadila , Sharvil Patel , Cadila Healthcare Ltd Zydus , Cadila Healthcare Ltd , Pegylated Interferon Alpha , Drugs Controller General , Interferon Alpha , Pegylated Interferon , Indian Innovation , Managing Director , Cadila Healthcare , Cadila Pharmaceuticals , Generic Pharmaceuticals , Drugs Controller General Of India , Antiviral Drugs , Zycov D , ஜய்துச் காடிலா , ஷார்வில் படேல் , காடிலா சுகாதாரம் லிமிடெட் ஜய்துச் , காடிலா சுகாதாரம் லிமிடெட் , மருந்துகள் கட்டுப்படுத்தி ஜநரல் , இந்தியன் கண்டுபிடிப்பு , நிர்வகித்தல் இயக்குனர் , காடிலா சுகாதாரம் , காடிலா மருந்துகள் , ஜெநெரிக் மருந்துகள் ,